Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC
Clinical trial NCT07765836 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07765836
- Sponsor
- Massachusetts General Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2027-01-01
- Primary completion
- 2028-12-31
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.